> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Pharmaceutical Science Panel to Discuss Model-informed Development
- URL: https://www.fdaweb.com/pharmaceutical-science-panel-to-discuss-model-informed-development/
- Published: 2016-11-28T12:00:00.000Z
- Updated: 2026-09-14T21:50:37.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5137437

*Federal Register* Notice: FDA has announced a 3/15/2017 Pharmaceutical Science and Clinical Pharmacology Advisory Committee that will discuss the use of model-informed drug development (MIDD) for new and generic drugs, which has significantly increased over the past several years. The committee will discuss strategies, approaches, and challenges in MIDD with specific focus on two areas. During the morning session, the committee will discuss approaches and evidentiary information needed for applying physiologically-based pharmacokinetic modeling and simulation throughout a drug’s lifecycle. During the afternoon session, the committee will discuss mechanistic model-informed safety evaluation with a focus on drug potential for causing arrhythmias. To view the notice, click [here](https://s3.amazonaws.com/public-inspection.federalregister.gov/2016-28605.pdf?ref=fdaweb.com).